Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes
2016
Autori:
Ludwig, GerdMojić, Marija
Bulatović, Mirna
Mijatović, Sanja
Maksimović-Ivanić, Danijela
Steinborn, Dirk
Kaluđerović, Goran N
Tip dokumenta:
Članak u časopisu (Objavljena verzija)
,
© 2016 Bentham Science Publishers
Metapodaci
Prikaz svih podataka o dokumentuApstrakt:
In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1-4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5-8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1-4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug's tumoricidal action on 8505C cell line.
Ključne reči:
Apoptosis; Autophagy; Caspase; Cisplatin; Iridium(III) complexes; Ruthenium(II) complexesIzvor:
Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 11, 1455-1460Finansiranje / projekti:
- Molekularni mehanizmi fiziološke i farmakološke kontrole inflamacije i kancera (RS-MESTD-Basic Research (BR or ON)-173013)
DOI: 10.2174/1871520615666151029100749
ISSN: 1871-5206
PubMed: 26510901